- Home
- LYEL vs TGTX Comparison
LYEL vs TGTX Comparison
Compare LYEL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- TGTX
- Stock Information
- Founded
- LYEL 2018
- TGTX 1993
- Country
- LYEL United States
- TGTX United States
- Employees
- LYEL N/A
- TGTX N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- LYEL Health Care
- TGTX Health Care
- Exchange
- LYEL Nasdaq
- TGTX Nasdaq
- Market Cap
- LYEL 207.7M
- TGTX 4.2B
- IPO Year
- LYEL 2021
- TGTX 1995
- Fundamental
- Price
- LYEL $13.13
- TGTX $31.75
- Analyst Decision
- LYEL Sell
- TGTX Strong Buy
- Analyst Count
- LYEL 2
- TGTX 4
- Target Price
- LYEL $15.00
- TGTX $42.50
- AVG Volume (30 Days)
- LYEL 25.5K
- TGTX 2.0M
- Earning Date
- LYEL 11-06-2025
- TGTX 11-03-2025
- Dividend Yield
- LYEL N/A
- TGTX N/A
- EPS Growth
- LYEL N/A
- TGTX N/A
- EPS
- LYEL N/A
- TGTX 0.36
- Revenue
- LYEL $60,000.00
- TGTX $454,069,000.00
- Revenue This Year
- LYEL N/A
- TGTX $82.58
- Revenue Next Year
- LYEL N/A
- TGTX $44.99
- P/E Ratio
- LYEL N/A
- TGTX $87.91
- Revenue Growth
- LYEL 11.11
- TGTX 30.96
- 52 Week Low
- LYEL $7.65
- TGTX $21.16
- 52 Week High
- LYEL $32.00
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- LYEL 67.37
- TGTX 54.67
- Support Level
- LYEL $12.59
- TGTX $31.34
- Resistance Level
- LYEL $13.50
- TGTX $32.56
- Average True Range (ATR)
- LYEL 0.66
- TGTX 1.09
- MACD
- LYEL 0.16
- TGTX 0.45
- Stochastic Oscillator
- LYEL 87.41
- TGTX 68.33
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.